Two AI-assisted products for pharmacovigilance teams. Inno-Pulse screens multilingual social-media conversations. PV Journals screens local medical journals every week. Both flag potentially safety-relevant content, keep it traceable to the source and leave the final assessment to your PV specialists.
Try the live demos
Use them separately or together to cover both patient-generated content and published literature.
Identifies potential adverse-event mentions in multilingual social-media content, codes them to MedDRA and surfaces emerging patterns.
Screens local medical journals every week, flags potentially PV-relevant publications and prepares traceable output for expert review.
Safety-relevant information is buried in large volumes of multilingual, unstructured content. Manual screening across products, sources and markets is hard to scale, and emerging patterns are easy to miss.
Covers Facebook, Reddit and X/Twitter today. Other sources can typically be added in about one week, depending on source access and platform/API restrictions.
Identifies medicine and adverse-event information across languages and keeps the original text for expert review.
Detects medicines, brands and adverse events, and normalizes reactions to MedDRA Preferred Terms and System Organ Classes.
Filter separately by seriousness and severity, with every mention traceable to its original post.
Compares recent activity with historical patterns to surface unusual increases that may need further assessment.
Immediate notifications for potentially serious events, plus scheduled daily and weekly reports.
Focus expert review on prioritized, safety-relevant content instead of the full stream.
Track unusual changes across products, reactions, sources and markets.
Follow safety-related discussions around competitor products.
Local medical journals publish case reports and safety observations that international databases often miss. Screening them by hand every week is slow and hard to document. PV Journals automates the weekly cycle and keeps every step traceable.
The Kazakhstan demo covers 11 local medical journals. Sources, therapeutic areas, products and markets can be extended to your scope.
Each cycle checks source availability and new issues, and compares them with the last screened issue.
Search rules combine brand names, INNs, active substances, synonyms and local generics with adverse-reaction terms in English, Russian and Kazakh.
Flagged publications come with metadata, supporting text, source references and the reason they were flagged.
A reviewer-ready list and weekly tracking table, in the dashboard and as an Excel export.
Previous runs, search parameters and reports are retained for historical review and traceability.
Regulatory alignment. Designed to support literature-screening workflows aligned with EMA GVP principles and EAEU pharmacovigilance requirements, with source-level traceability, reproducible search logic and retained screening history.
Reduce the weekly workload while keeping the process transparent.
Track safety information across all products with the same active substance and compare findings across brands.
Your qualified PV team gets a clear, documented basis for assessment.
Both products use AI for screening, structuring and prioritization. Final medical assessment, ICSR qualification, signal evaluation and regulatory decisions remain with your qualified PV team.
Every finding stays traceable to its original post or publication. Detected mentions are not automatically treated as regulatory-valid ICSRs.
Scope is configured around your products, competitors, markets, languages and sources. It complements your existing pharmacovigilance processes rather than replacing them.
Tell us which products, markets and sources matter to you. We'll set up a walkthrough around your monitoring scope.
Explore both products with these demo accounts:
